Contraindicated for use in CHF patients
Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Such activity has been shown to decrease survival compared to placebo in patients with class III-IV CHF.
Contraindicated in patients with CHF of any severity.
Patient counseling
Package inserts
Additional information
Updated: January 2018
This information provides a SUMMARY of Black Box data from product labeling and does not address all warnings, precautions, or important safety data found in the product insert. It is NOT intended for use in medical decision-making. Patients and healthcare professionals should always consult the most recent product information insert available from the manufacturer, and contact a physician or care provider with any questions. This table may not be complete and may not include all boxed warnings. It is periodically updated with supplemental information from FDA safety alerts, labeling announcements, and new drug approvals.
Formweb is a product of Rpharmy, LLC.
Visit our website at rpharmy.com for more information on online formularies featuring Black Box Warnings.